SRRK: Apitegromab nears FDA approval as a first-in-class SMA therapy, with global launch plans underway
Apitegromab is poised for FDA approval as the first muscle-targeted therapy for SMA, following strong phase III results and a successful transition to a new manufacturing facility. Broad demand is anticipated, with robust launch preparations, global expansion plans, and strategies in place to addre…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.